用αβ谱仪测量人工αβ放射性气溶胶体积活度的试验研究

本文介绍了用αβ谱仪系统同时测量αβ谱、实现Ｒｎ／Ｔｈ子体补偿、确定超铀α核素气溶胶体积活度及人工放射性气溶胶总β体积活度的技术途径。利用ＲａＡ、ＲａＣ′ａ峰的二段时间计数可确定空气中ＲａＡ、ＲａＢ、ＲａＣ的气溶胶体积活度，相应的，也能给出ＲａＢ、ＲａＣ对总β计数的贡献。根据一般环境条件下的平衡比，用ＴｈＣ′的。计数修正Ｔｈ子体对αβ测量的影响。￣［２３９］ｐｕ或／和￣［２４１］Ａｍ人工核素的α计数，可通过两段时间分别扣除ＲａＡ、ＲａＣ′拖尾的方法确定；β计数分别扣除Ｒｎ／Ｔｈ子体β贡献即可确定。在本文规定的测量条件下，对室内天然Ｒｎ子体水平在１５Ｂｑ／ｍ￣３以下，超铀α核素气溶胶体积活度的测量下限可达到０．１Ｂｑ／ｍ￣３；即使在７５Ｂｑ／ｍ￣３环境下，人工核素总β的测量下限也可达ｌＢｑ／ｍ￣３以下。     

Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas

ND10 are recently characterized nuclear domains that are composed of 0.5 microm sized, precisely circumscribed dots in cultured human cell lines. To investigate the distribution and number of ND10 on various types of normal and neoplastic human tissues, we carried out immunostaining and immunoprecipitation analyses with monoclonal antibodies 138 and 1150. The number of ND10 varied from 1 to 10 or more in various tissues as did their size. ND10 were diffusely located in early embryonic and normal tissues, except for the exocrine and endocrine cells of the pancreas and for hepatocytes. In normal squamous mucosa, basal cells had more ND10 than did differentiated superficial squamous cells. The number and size of ND10 were markedly increased in malignant neoplasms but were similar in benign tumors and corresponding normal tissues. Sex hormone-related normal tissues, such as the endometrium or myometrium, and neoplasms strongly stained for ND10. The distribution pattern of ND10 in human tissues indicates that they are conserved nuclear substructures that are closely associated with cellular differentiation, hormonal stimulation, and oncogenesis.     

直接斜率波前复原算法的控制效果分析

建立自适应光学系统功率谱抑制函数的概念，分析了采用直接斜率波前复原算法的自适应当光学系统的控制效果，理论分析与６１单元自适应光学系统上的实验结果表明，直接斜率波前复原算法将导致控制效果下降。     

Plasma properties of laser-ablated St target in air

Ｐｌａｓｍａｐｒｏｐｅｒｔｉｅｓｏｆｌａｓｅｒ－ａｂｌａｔｅｄＳｔｔａｒｇｅｔｉｎａｉｒＷａｎｇＸｉａｎｇ－Ｔａｉ（王象泰）；ＭａｎＢａｏ－Ｙｕａｎ（满宝元）；ＷａｎｇＧｏｎｇ－Ｔａｎｇ（王公堂）；ＦａｎＸｉ－Ｊｕｎ（樊锡君）；ＷａｎｇＪｕｎ（王军）...     

制备2，4－二氯－5－氟苯甲酰乙酸甲酯的缩合剂及工艺研究

通过３种不同的碱来制备２，４－二氯－５－氟苯甲酰乙酸甲酯，优选得到了其最佳缩合剂甲醇钠；同时应用正交设计实验，研究了原料配比、反应时间、反应温度对收率的影响，在优选条件下收率为７８．５％。     

Surgical treatment of unilateral alveolar cleft

In this study, 16 cases of unilateral alveolar cleft with cleft lip and palate were repaired with autografts of cancellous bone (13 cases) or hydroxyapatite (3 cases). The grafts were covered by reflected mucoperiosteal flaps and a mucosal flap from the upper lip. Twelve of the thirteen cases were followed up for 1-5 years. Nine of whom using cancellous bone had bony continuity of the maxilla and 7 cases erupted permanent maxillary canines within the area of autografts. None of the 3 cases using hydroxyapatite erupted a canine tooth. The results showed that autograft was better than hydroxyapatite in terms of maxillary canine eruption.     

The decision-making properties of discrete multiple exponentialbidirectional associative memories

A method for modeling the learning of belief combination in evidential reasoning using a neural network is presented. A centralized network composed of multiple exponential bidirectional associative memories (eBAM's) sharing a single output array of neurons is proposed to process the uncertainty management of many pieces of evidence simultaneously. The stability of the proposed multiple eBAM network is proved. The sufficient condition to recall a stored pattern pair is discussed. Most important of all, a majority rule of decision making in presentation of multiple evidence is also found by the study of signal-noise-ratio of multiple eBAM network. A guaranteed stable state condition, i.e., the condition for the fastest recall of a pattern pair, is also studied. The result is coherent with the intuition of reasoning.     

BID: a novel BH3 domain-only death agonist

The BCL-2 family of proteins consists of both antagonists (e.g., BCL-2) and agonists (e.g., BAX) that regulate apoptosis and compete through dimerization. The BH1 and BH2 domains of BCL-2 are required to heterodimerize with BAX and to repress cell death; conversely, the BH3 domain of BAX is required to heterodimerize with BCL-2 and to promote cell death. To extend this pathway, we used interactive cloning to identify Bid, which encodes a novel death agonist that heterodimerizes with either agonists (BAX) or antagonists (BCL-2). BID possesses only the BH3 domain, lacks a carboxy-terminal signal-anchor segment, and is found in both cytosolic and membrane locations. BID counters the protective effect of BCL-2. Moreover, expression of BID, without another death stimulus, induces ICE-like proteases and apoptosis. Mutagenesis revealed that an intact BH3 domain of BID was required to bind the BH1 domain of either BCL-2 or BAX. A BH3 mutant of BID that still heterodimerized with BCL-2 failed to promote apoptosis, dissociating these activities. In contrast, the only BID BH3 mutant that retained death promoting activity interacted with BAX, but not BCL-2. This BH3-only molecule supports BH3 as a death domain and favors a model in which BID represents a death ligand for the membrane-bound receptor BAX.